ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Field of Research : Infectious Diseases
Research Topic : Virus evolution
Clear All
Filter by Field of Research
Infectious Diseases (46)
Filter by Socio-Economic Objective
Search did not return any results.
Filter by Funding Provider
National Health and Medical Research Council (46)
Filter by Status
Closed (46)
Filter by Scheme
NHMRC Project Grants (15)
Project Grants (9)
Career Development Fellowships (6)
Early Career Fellowships (5)
Postgraduate Scholarships (3)
NHMRC Postgraduate Scholarships (2)
Practitioner Fellowships (2)
Research Fellowships (2)
NHMRC Research Fellowships (1)
Program Grants (1)
Filter by Country
Australia (4)
Filter by Australian State/Territory
NSW (3)
ACT (1)
SA (1)
VIC (1)
  • Researchers (4)
  • Funded Activities (46)
  • Organisations (23)
  • Funded Activity

    Structural Analysis Of Poxvirus Immature Particles And Spheroids

    Funder
    National Health and Medical Research Council
    Funding Amount
    $387,489.00
    Summary
    Despite the eradication of smallpox by vaccination, poxviruses remain a threat to public health because of bioterrorist scares from kept variola stocks and because of the possible emergence of other poxvirus pathogens from the extensive animal reservoir. The structural analysis of the assembly of poxvirus will not only improve our knowledge of fundamental processes, highly conserved in DNA viruses, but could also provide valuable targets for the rational design of antiviral drugs.
    More information
    Funded Activity

    Characteristics And Mechanisms Of Persistent Asthma After Common Cold Virus Infection

    Funder
    National Health and Medical Research Council
    Funding Amount
    $407,750.00
    Summary
    Asthma is a major health problem for the Australian community. Recent studies have shown increasing numbers of people of all ages are developing asthma, and despite a fall in asthma deaths, large number of people continue to have severe attacks requiring hospitalisation. In most cases the deterioration in asthma symptoms is related to a cold or flu like illness. Viruses are the leading cause of these infections and are known to make asthma symptoms worse. We have identified how viruses do this b .... Asthma is a major health problem for the Australian community. Recent studies have shown increasing numbers of people of all ages are developing asthma, and despite a fall in asthma deaths, large number of people continue to have severe attacks requiring hospitalisation. In most cases the deterioration in asthma symptoms is related to a cold or flu like illness. Viruses are the leading cause of these infections and are known to make asthma symptoms worse. We have identified how viruses do this by triggering a type of inflammation in the airways. We have also found that after a severe attack of asthma some people do not recover completely. They appear to have persistent problems, and in some cases the virus can still be isolated from the airways. How and why this occurs is not known. We are seeking to understand this problem and describe how it affects people with asthma. We plan to investigate what effect certain viruses have on the lungs of people with asthma by measuring cells and chemicals that are present in sputum. We will use recently developed technologies to accurately see what viruses are infecting these people, and how the immune system is working. This study will shed important light on potential causes of unstable asthma and the role that viral infection plays in this. It may also lead to new opportunities to develop treatments that are more effective in preventing and controlling asthma.
    Read more Read less
    More information
    Funded Activity

    Early Treatment Of Hepatitis C Virus In Australia

    Funder
    National Health and Medical Research Council
    Funding Amount
    $113,322.00
    Summary
    Hepatitis C affects between 1-3% of Australians. Currently, there is no effective vaccine and only 30% will spontaneously clear infection, while the remained develop a chronic disease with a small risk of progression to liver cirrhosis and liver cancer over time. This study aims to evaluate the safety and efficacy of a two different treatment regimens among individuals with recent Hepatitis C infection; and define the risk factors and natural history of Hepatitis C superinfection during treatmen .... Hepatitis C affects between 1-3% of Australians. Currently, there is no effective vaccine and only 30% will spontaneously clear infection, while the remained develop a chronic disease with a small risk of progression to liver cirrhosis and liver cancer over time. This study aims to evaluate the safety and efficacy of a two different treatment regimens among individuals with recent Hepatitis C infection; and define the risk factors and natural history of Hepatitis C superinfection during treatment.
    Read more Read less
    More information
    Funded Activity

    Regulation Of Subcellular Localisation Of Respiratory Syncytial Virus M Protein: Implications For Pathology

    Funder
    National Health and Medical Research Council
    Funding Amount
    $580,195.00
    Summary
    Respiratory syncytial virus (RSV) is the major cause of viral pneumonia in infants and the elderly, causing more deaths in winter than influenza. We have observed RSV M protein in the nucleus of infected host cells where it inhibits host cell transcription. We propose to investigate the regulation of nuclear localisation of M by phosphorylation and binding to cellular factors and its importance to RSV pathogenesis. The results will relate strongly to future drug and vaccine development.
    More information
    Funded Activity

    The Impact Of Influenza A Virus PB1-F2 Protein On Host Immunity And The Potential For Therapeutic Targeting

    Funder
    National Health and Medical Research Council
    Funding Amount
    $317,076.00
    Summary
    The 1918 influenza virus pandemic resulted in 50 million deaths globally and there is potential for new pandemics, such as the predicted H5N1 Bird Flu . Exact causes of such devastating lethality are not fully identified. Newly discovered influenza A virus (IAV) PB1-F2 protein is present in nearly all highly pathogenic IAVs and promotes virus virulence. This study will further examine the way in which PB1-F2 impacts the host, revealing potential therapeutic targets to lessen disease burden.
    More information
    Funded Activity

    Application Of Mathematical Modelling And Development Of Decision Support Tools For Mosquito-borne Disease

    Funder
    National Health and Medical Research Council
    Funding Amount
    $380,558.00
    Summary
    Mosquito-borne disease affects millions of people in Australia and overseas. Reducing the prevalence of these diseases requires an understanding of their transmission, drug resistance and role of external factors such as climate. This project will use newly developed mathematical and statistical tools to investigate transmission of malaria, and improve the reporting of Ross River and Barmah Forest viruses and dengue. Project outcomes will assist the development of evidence based policy.
    More information
    Funded Activity

    Uncoupled Research Fellowship

    Funder
    National Health and Medical Research Council
    Funding Amount
    $765,881.00
    Summary
    I am a physician-scientist whose research involves the role of monocyte-macrophages in HIV pathogenesis and low cost methods for monitoring HIV infection in resource-constrained countries
    More information
    Funded Activity

    Studies Of HIV And HBV Co-infection.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $135,770.00
    Summary
    There are a number of patients throughout Victoria that are co-infected with both hepatitis B virus (HBV) and human immunodeficiency virus (HIV). These patients are currently being treated for HIV with multiple antiviral drugs and are living for longer periods. Lamivudine is one of the drugs in the HIV antiviral treatment regime. This antiviral is also effective against hepatitis B virus and is the only licensed nucleoside analogue that is used in the treatment of hepatitis. The aim of this proj .... There are a number of patients throughout Victoria that are co-infected with both hepatitis B virus (HBV) and human immunodeficiency virus (HIV). These patients are currently being treated for HIV with multiple antiviral drugs and are living for longer periods. Lamivudine is one of the drugs in the HIV antiviral treatment regime. This antiviral is also effective against hepatitis B virus and is the only licensed nucleoside analogue that is used in the treatment of hepatitis. The aim of this project is to investigate the liver disease caused by HBV in co-infected patients and the development of antiviral resistance due to the long-term treatment with lamivudine. We will develop a data base to monitor virological, biochemical and histological parameters for each of these co-infected patients. We will collate all information on these patients that are attending these various centres. This data base will be essential for monitoring the disease in patients with a poor immune system versus patients with a normal immune system. The HBV virus isolated from these patients will be characterised by sequence analysis. The sequence analysis of these viruses will be compared before and after treatment to determine any resistance markers that have developed. These resistant markers will be copied into an infectious clone using specialised molecular techniques. Clones containing these resistant markers will be analysed in the laboratory to determine the antiviral sensitivity to lamivudine and a number of new drugs against hepatitis B virus. This information will be important in treating patients that are co-infected with HBV and HIV and have already developed resistance to lamivudine.
    Read more Read less
    More information
    Funded Activity

    Role Of Nucleocytoplasmic Trafficking Of Matrix Protein In RSV Infection

    Funder
    National Health and Medical Research Council
    Funding Amount
    $495,041.00
    Summary
    Respiratory syncytial virus (RSV) is the major cause of viral pneumonia in infants and young children throughout the world. By the age of 3, virtually every child has been infected by RSV at least once. RSV is also an important cause of pneumonia in the elderly and is estimated to cause more deaths each winter than influenza. In Australia, an estimated 100,000 infants are infected by RSV every year. In Victoria, RSV is the most common cause of all reported cases of respiratory tract disease, wit .... Respiratory syncytial virus (RSV) is the major cause of viral pneumonia in infants and young children throughout the world. By the age of 3, virtually every child has been infected by RSV at least once. RSV is also an important cause of pneumonia in the elderly and is estimated to cause more deaths each winter than influenza. In Australia, an estimated 100,000 infants are infected by RSV every year. In Victoria, RSV is the most common cause of all reported cases of respiratory tract disease, with an estimated annual cost of $1-4 million. Despite more than 40 years of research there is no vaccine to prevent RSV infection, and the only drug (ribavirin) licenced for treatment of RSV infection is expensive, difficult to administer, toxic, and of doubtful efficacy. We propose to examine one of the RSV proteins, the matrix protein (M). M is very important for virus propagation and is responsible for resultant cell injury. We have observed that M enters the cell nucleus (the location for all cellular DNA and RNA synthesis) where it appears to inhibit host cell RNA synthesis early in infection; later, it exits the nucleus in a step required for virus production in the cytoplasm. The signals that regulate transport of M into and out of the nucleus and the effect on the host cell leading to pathogenesis, are the focus of this proposal. The results of this study will be beneficial in many ways. Most importantly, we will gain knowledge about the processes underlying cell injury caused in RSV disease, which may lead to the identification of novel targets for intervention strategies.
    Read more Read less
    More information
    Funded Activity

    West Nile Virus Replication And Host Response

    Funder
    National Health and Medical Research Council
    Funding Amount
    $560,434.00
    Summary
    We seek to gain a detailed understanding of how interactions between the West Nile virus proteins and host factors involved in the IFN response determine the outcome of virus infection. Better understanding of the mechanisms employed by this highly pathogenic virus to disable the mammalian host's IFN response will have wider implications for our understanding of other human diseases such as cancer, autoimmunity and provide new avenues for design of efficient antiviral and anticancer therapies.
    More information

    Showing 1-10 of 46 Funded Activites

    • 1
    • 2
    • 3
    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback